medigraphic.com
ISSN 1029-3035 (Electronic)

2015, Number 2

<< Back Next >>

Mediciego 2015; 21 (2)

Effects of the use of carvedilol in dilated cardiomyopathy in pediatric age

Samper MH, Pérez MD, Baró RM, Sánchez CE, Reyes QY

Language: Spanish
References: 35
Page: 106-116
PDF size: 115.04 Kb.


ABSTRACT

Introduction: dilated cardiomyopathy is the most common worldwide cardiomyopathy. In pediatric patients, the annual incidence is 0.5-1.2 cases per 100,000, with 8-12 times more common presentation in infants (4.4 per 100,000) than in older children. Considering the limited prognosis of long-term cardiac transplantation and absence of adequate pediatric donors, all strategies that seek to improve current medical treatments and investigate alternative therapeutic options are justified. Development: a bibliographic review was carried out with the aim of knowing the use effects of carvedilol in dilated in pediatric age. Dilated cardiomyopathy is characterized by a massive cardiomegaly secondary to wide enlarged ventricles. The prevalence in the child population is 36.5 per 100 000 live births, aggressive treatment of heart failure can make a temporary remission, but relapses are common and patients that tend to become resistant to the usual medication. Conclusions: the introduction of carvedilol in the pediatric treatment of these diseases is relatively new, and requires a study of the issue further.


REFERENCES

  1. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes and outcomes of dilated cardiomyopathy in children. JAMA. 2009;296:1867-76.

  2. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin. 2010;6:401-13.

  3. Nugent AW, Daubeney PE, Chondros P. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2009;348:1639-46.

  4. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647-55

  5. Perich Durán RM, Albert Brotons D, Zaba-la Argüelles I, Malo Concepción P. Temas de actualidad en cardiología pediátrica y cardiopatías congénitas. Rev Esp Cardiol. 2010;61:15- 26.

  6. Galve Basilio E, Alfonso Manterota F, Ballester Rodés M. Guías de práctica clínica de la Sociedad Española de Cardiología en miocardiopatías y miocarditis. Rev Esp Cardiol. 2011;53:360-93.

  7. Moruno A, García-Angleu F, Coserria F. Miocardiopatías en la infancia. An Pediatr Contin. 2009;5(2):77-84.

  8. Richardson P, McKenna WJ, Bristow M, Maisch B, Mautner B, O’Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of the Cardiomyopathies. Circulation. 2009;93:841-2

  9. Navarro Puerto MA, Cubero Gómez JM, Melguizo Moya I, Gómez Herreros R. Definición y clasificación de las miocardiopatías. Guía Clínica [Internet]. A Coruña: Fisterra; 2011 [citado 12 May 2014]. Disponible en: http://www.fisterra.com/guias-clinicas/definicion-clasificacionmiocardiopatias/

  10. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2012;113:1807-16.

  11. Elliot P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and pericardial Diseases. EurHeart J. 2009;29:270-6.

  12. Moretín B, Suárez-Mier MP, Aguilera B, Bodegas A. Mortalidad por enfermedades del miocardio en niños y jóvenes. Estudio observacional de base poblacional. Rev Esp Cardiol. 2009;59:238-46.

  13. Taliercio CP, Seward JB, Driscoll DJ, Fisher LD, Gersh BJ, Tajik AJ. Idiopathic dilatated cardiomyopathy in the young:clinical profile and natural history. J Am Coll Cardiol. 2009;6:11-26.

  14. Chen SC, Nouri S, Balfour I, Jureidini S, Appleton RS. Clinical profile of congestive cardiomyopathy in children. J Am Coll Cardiol. 2011;15:189

  15. Matitiau A. Infantile dilated cardiomyopathy: relation of outcome to left ventricular mechanics, hemodynamics and histology at the time of presentation. Circulation. 2010;90:1310.

  16. Michels VV et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med. 2009;326:77

  17. Griffin ML. Dilated carrdiomyopathy in infants and children. Jam Coll Cardiol. 2010;11:139.

  18. Limas CJ, Limas C. HLA-DR antigen linkage and anti-receptor antibodies in idiopathic dilated and ischemic cardiomyopathy. Br Heart J. 1992;67(5):402-5.

  19. Roberts WC, Siegel RJ, McManus BM. Idiopathic dilated cadriomyopathy analysis of 152 necropsy patients Am J Cardiol. 2009;60:1340.

  20. Doshi R, Lodge KV. Idiopathic cardiomyopathy in infants. Arch Dis Child. 1973;48(6):431-5.

  21. Figarella-Branger D, Pellissier JF, Scheiner C, Wiernert F, Desnuelle C. Defects of the mitochondrial respiratory chain complexes in three pediatric cases with hypotonia and cardiac involvemente. J Neurol Sci. 2010;108:105-13.

  22. Orstavik KH, Skjorten F, Hellebostad M, Haga P, langslet A. Possible X linked congenital mitochondrial cardiomyopaphy in three families. J Med Gent. 2009;30:262-9.

  23. Hodgson S, Child A, Dyson M. Endocardialfibroelastosis: possible X linked inheritance. L Med Genet. 2009;24:210.

  24. Stumpf DA, Parks JK, Eguren LA, Haas R. Friedreich ataxia. III: Mitochondrial malic enzyme deficiency. Neurology. 2010;32:221.

  25. Tripp ME. Metabolic cardiomyopathies. Prog Pediatr Cardiol. 1992;1(4):1-12.

  26. Treem WR, Stanley CA, Finegold DA, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitina transport in kidney, muscle and fibroblast. N Engl J Med. 2011;319:1331.

  27. Eriksson BO, Lindstedt S, Nordin I. Hereditary defect in carnitine transport is expessed in skin fibroblasts. Pediatr Res. 2012;2(8):247.

  28. Tein I, DeVivo DC, Bierman F, Pulver P, DeMierleir IJ, Cvitanovic-Sojat L, et al. Impaired skin fibroblasts carnitine uptake in primary systemic carnitinedeficienciency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res. 2012;28:247.

  29. Angelini C. defects of fatty -acid oxidation in muscle. Baillieres Clin Endocrinol Metb. 2009;4:561-82.

  30. Ino T, Sherwood WG, Benson LN, Wilson GJ, Freedom RM, Rowe RD. Cardiac manifestations in disorders of fat and carnitine metabolism in infancy. J Am Coll Cardiol. 2009;11:1301-8

  31. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 2011;26:271

  32. Marian AJ, Roberts R. Molecular genetics of cardiomyopathies. Herz. 2009;18:230.

  33. Bhattacharya SK, Crawford AJ, Pate JW. Electrocardiographic, biochemical, and morphologic abnormalities in dystrophic hamsters with cardiomyopathy. Muscle Nerve. 2009;10:168.

  34. Roberds SL, Ervasti JM, Anderson RD. Disruption of the dystrophin-glycoprotein complex in the cardiomyopathic hamster. J Biol Chem. 2009;268:1146

  35. Yamakawa K. Study of immunologic mechanism in dilated cardiomyopathy. Jpn Circ J. 2009;51:665.




2020     |     www.medigraphic.com